baber/WOPTO huggingface dataset:
Patent DE-69427468-T2 (DE)
Inventor: ROMEO AURELIO
IPC: C07H15/10
Filed: 1994-03-04
Granted: 2002-04-18
Abstract: Semisynthetic analogues of gangliosides selected from the group consisting of N-sulfo-, N-hydrocarbyl-sulfonyl- and N-hydrocarbyloxy-sulfonyl-N,N'-dilyso-gangliosides and the N'-acyl derivatives thereof, N'-sulfo-, N'-hydrocarbylsulfonyl- and N'-hydrocarbyloxy-sulfonyl-N,N'-dilyso-gangliosides and the N-acyl derivatives thereof, N,N'-di or polysulfo-N,N'-di- or poly-lyso-gangliosides, N,N'-di- or polyhydrocarbylsulfonyl-N,N'-di- or poly-lyso-gangliosides and N,N'-di- or polyhydrocarbyloxy-N,N'-di- or poly-lyso-gangliosides, and functional derivatives thereof, and salts of these compounds, have protective activity against neurotoxicity induced by excitatory amino acids and are foreseen to be used in therapy in the nervous system and in modulating of the expression of determinants such as CD4 on the surface of human cells in the immune system.
Patent DE-69430094-T2 (DE)
Inventor: NISHIBAYASHI YOSHIKI
IPC: H01L29/16
Filed: 1994-09-06
Granted: 2002-11-21
Abstract: A diamond semiconductor device of the present invention comprises an n-type diamond layer to which an n-type dopant is doped at high concentration so that metal conduction dominates, a p-type diamond layer to which a p-type dopant is doped at high concentration so that metal conduction dominates, and a high resistance diamond layer formed between the n-type diamond layer and the p-type diamond layer. Here, the thickness and the doping concentration of the high resistance diamond layer are values at which semiconductor conduction dominates. Then, in a case that an applied voltage is forward bias, electrons are injected from the n-type region to the p-type region through the conduction band of the high resistance region, and holes are injected from the p-type region to the n-type region through the valance band of the high resistance region, so that a current flows. On the other hand, in a case that an applied voltage is reverse bias because substantially no dopant is doped to the high resistance diamond layer, carriers are not present, so that a large current does not flow. Therefore, semiconductor conduction dominates as carrier conduction in pn junction and the rectification can be obtained, so that with the control of carriers, good diode characteristics or transistor characteristics can be achieved.
Patent DE-69505802-T2 (DE)
Inventor: POILLUCCI GIOVANNI
IPC: F17C1/00
Filed: 1995-07-07
Granted: 1999-04-01
Abstract: An improved fluid-tight, openable, protective container (1, 2, 3, 4) for the underground installation of a tank of pressurized, liquefied gas (14) with the formation of an interspace (17) between the container and the tank housed therein, in which the container has a top (3) which has a hatch (4) and is fixed removably to a peripheral wall (1) and which forms, with a connecting collar (12) of the hatch (4), a semitoroidal housing for a sealing ring (13) for separating the interspace (17) from a space inside the hatch (4), the semitoroidal housing having an outer edge (18) for bearing on the tank (14) to ensure a predetermined compression of the seal (13), an opening of predetermined depth (H1) between an inner edge (20) of the housing and the tank (14), and differentiated sealing by the seal (13) under excess pressures according to whether these develop in the interspace (17) or in the space inside the hatch (4). The outer edge (18) has at least one radial channel which enables inspection probes to be introduced into the interspace from the hatch simply by the removal of the seal (13), without the need to remove the top (3). <IMAGE>
Patent DE-69513673-T2 (DE)
Inventor: LIANG SHAOWO
IPC: C07C233/58
Filed: 1995-09-18
Granted: 2000-05-25
Abstract: The present invention provides a process for the preparation of cyclopropanecarboxamide which comprises the steps of:   (1) contacting cyclopropanecarboxylic acid with ammonia in a reactor at a temperature of 200 to 260 DEG C and a pressure of 10 to 100 bar absolute in the absence of both a catalyst and a solvent to form a melt of cyclopropanecarboxamide; (2) venting the reactor at a temperature above the melting point of cyclopropanecarboxamide to reduce the pressure to atmospheric pressure and remove excess ammonia and water of reaction from the cyclopropanecarboxamide; and (3) obtaining from the reactor cyclopropanecarboxamide essentially free of water and ammonia.
Patent DE-69518006-T2 (DE)
Inventor: AMEY JAMES
IPC: A61K9/48
Filed: 1995-11-09
Granted: 2000-12-21
Abstract: A process for encapsulation of caplets in a capsule comprises the following steps: a. providing empty capsule parts; b. filling at least one of said capsule parts with one or more caplets; c. putting said capsule parts together; and d. treating the combined parts by cold shrinking. The solid dosage forms obtainable by such aprocess are tamper-proof in that they cannot be opened in a way to be reassembled without showing such opening process.
Patent DE-69527439-T2 (DE)
Inventor: FIORETTI WILLIAM C
IPC: A61K38/16
Filed: 1995-02-28
Granted: 2003-02-20
Abstract: The present invention relates to a method of accelerating the onset of puberty in avians, especially ratites and psittaciformes, by administering a heterologous protein comprising inhibin, or a fragment thereof, and a carrier protein. The present invention also relates to a method of increasing egg production in animals, particularly birds, more particularly ratites, via the administration of the heterologous protein. This invention further relates to the heterologous protein and a method for producing the heterologous protein. The heterologous protein can be either inhibin conjugated to the carrier protein or inhibin fused to the carrier protein. The method of producing the fused heterologous protein comprises inserting double stranded cDNA encoding inhibin, or a fragment thereof, into a vector which encodes a carrier protein such as maltose binding protein or bovine serum albumin. After inserting the vector into an expression system, the fused heterologous protein is expressed by the system. After purifying the expressed heterologous protein, an effective amount of the protein is administered to an animal such that an immunological response occurs in the animal against the heterologous protein.
Patent DE-69527657-T2 (DE)
Inventor: CAPPELLETTI MARIELLA
IPC: C12M3/00
Filed: 1995-05-18
Granted: 2003-04-03
Abstract: PCT No. PCT/IT95/00083 Sec. 371 Date Nov. 17, 1997 Sec. 102(e) Date Nov. 17, 1997 PCT Filed May 18, 1995 PCT Pub. No. WO96/36703 PCT Pub. Date Nov. 21, 1996Secondary metabolites of viable plant cells are produced with the cells immobilized in a porous inorganic support. Immobilization includes the steps of: (a) preparing a support comprising a substantially uniform and porous matrix of inorganic material having a tensile strength of at least 500 MPa; (b) introducing a culture of viable plant cells into the pores of said matrix; (c) entrapping the plant cells by coating the matrix with a sol or colloidal suspension not interfering with the cell viability; and (d) immobilizing the entrapped cells within the matrix with a reactive gas including a carrier gas saturated with volatile SiO2 or organic modified SiO2 precursors. The tensile strength may be provided by impregnating the matrix with a gelling solution of SiO2 precursor for increasing stiffness of the matrix. The matrix may be a SiO2 or inorganic oxide matrices, in which the weight ratio between cell load and inorganic matrix ranges between 1x10-4 and 1x10-2. The immobilized cells are not released in solution over a period of 6 months and maintain their viability while producing secondary metabolites.
Patent DE-69527706-T2 (DE)
Inventor: THEOHARIDES C
IPC: A61K31/445
Filed: 1995-02-09
Granted: 2002-11-28
Abstract: A method for treating endogenous, painful gastrointestinal condition of non-inflammatory, non-ulcerative origin, such as abdominal migraine and irritable bowel syndrome, entails administering a pharmacologically effective amount of a mast cell degranulation-blocking agent, e.g. a histamine-3 receptor agonist.
Patent DE-69527943-T2 (DE)
Inventor: KATO YASUYOSHI
IPC: B01D53/86
Filed: 1995-11-14
Granted: 2003-01-02
Abstract: A catalyst unit comprising a housing having an inlet, an outlet and side walls extending therebetween, said inlet and outlet defining a direction for gas flow therebetween as an axial direction; a plurality of catalyst plate elements mounted within said housing between said inlet and said outlet to form a stack, each catalyst plate element supporting a catalytic material and having parallel ribs spaced across one dimension thereof with flat sections separating the ribs; is characterized in that adjacent catalyst plate elements in said stack are contacted between their respective ribs, whereby the ribs of adjacent catalyst plate elements define a contact angle of 90 DEG  therebetween, and the ribs of at least one catalyst plate elements are arranged at 90 DEG to said axial direction, and opposing edges of said at least one catalyst plate, respectively traversing said inlet and said outlet, are each spaced a distance L from the center of the rib closest thereto and wherein L ≤ 8 T, wherein T is the spacing between the flat sections of adjacent catalyst plate elements. <IMAGE>
Patent DE-69528379-T2 (DE)
Inventor: HUDSON PETER L
IPC: C12N5/06
Filed: 1995-06-28
Granted: 2003-06-12
Abstract: Human serum paraoxonase enzyme and DNA (RNA) encoding such serum paraoxonase enzymes are disclosed. Also provided is the procedure for producing such polypeptides by recombinant techniques. Uses of such polypeptides include their use as an antidote for organophosphate poisoning and to prevent neuronal cell death. Diagnostic assays for identifying mutations in a nucleic acid sequence encoding a polypeptide of the present invention and for detecting altered levels of the polypeptide of the present invention are also disclosed.
Patent DE-69534228-T2 (DE)
Inventor: ZUCKERMAN RALPH
IPC: A61B5/1459
Filed: 1995-04-19
Granted: 2006-03-16
Abstract: Methods are described for the in vivo topographic determination of tissue and bodily fluid oxygen concentration or PO2 within an imaged tissue, as well as a method for measuring blood or bodily fluid PO2 with a fiber optic catheter. In the first method, a lipid soluble, biocompatible fluorescent probe substance is administered to an animal body and accumulates within the lipid bilayers of its tissue cells. In the second method, the fluorescent probe substance is conjugated to a large molecular mass protein which causes it to be retained within a bodily fluid such as blood. In the third method describing a catheter design, in which PO2 is measured at the catheter tip, the tip contains the fluorescent probe substance dissolved in a viscous nonpolar solvent. In all methods described, a fluorescent probe substance is preferred whose fluorescence lifetime is quenched by molecular oxygen, and oxygen concentration or PO2 is determined by measuring the fluorescence anisotropy of the fluorescent probe substance. The bodily fluid or tissue containing the biocompatible fluorescent probe substance, or the fluorescent probe substance in a nonpolar solvent within a catheter tip, is irradiated with continuous linearly polarized ultraviolet light at a wavelength strongly absorbed by the fluorophore. The emitted fluorescence is resolved into its vector components parallel and perpendicular to the plane of polarization of the excitation light, thereby permitting the calculation of the fluorescence anisotropy of the irradiated specimen. Tissue and/or bodily fluid PO2 of the imaged specimen, or the PO2 of a fluid at the tip of a sealed catheter, is determined by applying a mathematical function which relates the fluorescence anisotropy of an O2-quenchable fluorophore to oxygen concentration or partial pressure.
Patent DE-69534875-T2 (DE)
Inventor: BRYAN N
IPC: C12P21/02
Filed: 1995-04-28
Granted: 2006-11-16
Abstract: Novel calcium free subtilisin mutants are taught, in particular subtilisins which have been mutated to eliminate amino acids 75-83 and which retain enzymatic activity and stability. Recombinant methods for producing same and recombinant DNA encoding for such subtilisin mutants are also provided.
Patent DE-69612071-T2 (DE)
Inventor: NEGELEN EMANUEL
IPC: B65D71/48
Filed: 1996-12-17
Granted: 2001-08-09
Abstract: There is provided a carrier device (11) for a plurality of containers (12) each having an annular shoulder projecting from the neck portion. The device comprises a base (16) having apertures for receiving the respective neck portions of the containers (12), two side walls (19, 20) extending towards each other from opposite sides of the base (16) each having a cut away portion for engaging each container (12), upwardly projecting handle portions (23) which incorporate handle means (43) and into which the cut away portions extend to accommodate the container closures (14). The upwardly projecting handle portions (23) are hingedly connected to the side walls (19, 20) which each cut away portion having a flap portion (41) below which projections on the handle portions engage so that the handle portions (23) can be folded down so as to lie adjacent one side wall and to be retained in this configuration. <IMAGE>
Patent DE-69612397-T2 (DE)
Inventor: DE BRABANDER-VAN DEN BERG MARL
IPC: C08L23/02
Filed: 1996-11-15
Granted: 2001-11-08
Abstract: The invention relates to a composition comprising a plastic and an additive, the additive being present in a dendrimer having functional end groups, said functional end groups being provided, at least in part, with a modifying group, which modifying group is compatible with the plastic. The additive remains trapped in the dendrimer and, owing to the presence of the modifying group on the dendrimer, cannot migrate or bleed from the plastic.
Patent DE-69612496-T2 (DE)
Inventor: WASON KUMAR
IPC: A61K8/00
Filed: 1996-04-29
Granted: 2001-11-08
Abstract: Oral compositions, such as oral gels and toothpastes, containing a novel abrasive.
Patent DE-69616591-T2 (DE)
Inventor: HANAWA LTD
IPC: A01N63/00
Filed: 1996-12-20
Granted: 2002-09-05
Abstract: PCT No. PCT/JP96/03733 Sec. 371 Date Jun. 4, 1998 Sec. 102(e) Date Jun. 4, 1998 PCT Filed Dec. 20, 1996 PCT Pub. No. WO97/24134 PCT Pub. Date Jul. 10, 1997A composition containing natural drugs is disclosed. The composition is effective for relieving physical and mental fatigue and for ameliorating a weakened constitution without any side effects, even if administered for a long time.
Patent DE-69619283-T2 (DE)
Inventor: HEDNER JAN
IPC: A61K39/395
Filed: 1996-11-06
Granted: 2002-11-14
Abstract: A use of an antibiotic effective against H. pylori for the manufacture of a medicament for administration to mothers or other persons infected by H. pylori but lacking symptoms and coming into close bodily contact with infants below two years of age, for prevention of SIDS.
Patent DE-69632726-T2 (DE)
Inventor: GRACHECK JOSEPH
IPC: C07D498/04
Filed: 1996-01-26
Granted: 2004-10-14
Abstract: Benzothiophene, benzofuran and indolethiazepinones, oxazepinones, and diazepinones are effective therapeutic agents for treating viral diseases, including those caused by herpesvirus and HIV.
Patent DE-69634828-T2 (DE)
Inventor: ANTANOVICH D
IPC: A01N1/02
Filed: 1996-10-15
Granted: 2006-03-23
Abstract: Bioartificial implants and methods for their manufacture and use are described, particularly bioartificial pancreases. In particular, the implants may be thin sheets which enclose cells, may be completely biocompatible over extended periods of time and may not induce fibrosis. The high-density-cell-containing thin sheets are preferably completely retrievable, and have dimensions allowing maintenance of optimal tissue viability through rapid diffusion of nutrients and oxygen and also allowing rapid changes in the secretion rate of insulin and/or other bioactive agents in response to changing physiology. Implantations of living cells, tissue, drugs, medicines and/or enzymes, contained in the bioartificial implants may be made to treat and/or prevent disease.
Patent DE-69721783-T2 (DE)
Inventor: FLOOD A
IPC: B23K9/028
Filed: 1997-08-12
Granted: 2003-11-20
Abstract: A process for buttwelding metal workpieces having bevelled joint preparations using an automatic GTAW welder using filler wire includes preparing the bevelled workpiece with bevelled joint areas having minimal land thickness at the root extremities; placing the prepared workpiece joint sections together with an open gap between their adjacent root extremities, the gap having a minimum dimension that avoids harmful compression stress between the workpieces due to weld shrinkage and a maximum dimension that avoids filler wire penetration of the gap; fusion welding the open root area of the adjacent workpieces with a root pass weld using an automatic GTAW welder supplied with filler wire and a shield gas including 1 to 10% hydrogen and the balance inert gas; and then promptly overlaying the root pass weld with at least one additional filler weld pass using an automatic GTAW supplied with filler wire and hydrogen-free shield gas.
Patent DE-69729206-T2 (DE)
Inventor: BABA AKIO
IPC: C07D263/52
Filed: 1997-07-07
Granted: 2005-05-04
Abstract: The present invention produces novel cis-oxazolidinone compound which is racemic form or optically active form, of a formula (1) <CHEM> wherein R represents C1-C6 alkyl group, C2-C6 alkenyl group, C1-C6 alkoxyl group, C1-C6 alkylamino group, aryl group or halogen atom, and oxazolidinone ring is at cis-configuration, comprising reacting cis-1,2-indene epoxide of a formula (3) <CHEM>  form, with sulfonyl isocyanate compound of a formula (4) <CHEM>  in the presence of metal halide catalyst. Further, cis-1-amino-2-indanol is produced by hydrolyzing the oxazolidinone compound. The latter compound is useful as an intermediate of HIV-drug.
Patent DE-69730169-T2 (DE)
Inventor: FIKES W
IPC: G06K7/10
Filed: 1997-10-06
Granted: 2005-10-13
Abstract: A scanner and a method for scanning a beam along a path employs a housing tint defines a first cylindrical cavity. A ring gear is disposed within the cylindrical cavity and affixed to the housing. A beam is generated from a fixed location relative to the housing. A drive disk is disposed within the first cylindrical cavity. The drive disk defines a second cylindrical cavity and has a first axis of rotation. The drive disk defines a first channel in communication with the beam. The first channel has a first proximal end pivotally rotatable about an axis adjacent the fixed location. A scan disk is disposed within the second cylindrical cavity and has a second axis of rotation offset from the first axis of rotation. The scan disk defines a second channel. The second channel has a second proximal end in communication with the first distal opening. The second proximal end pivotally rotates about an axis adjacent the first distal end. A ring motor causes the drive disk to rotate about the first axis in a first direction. A spur gear, affixed to the scan disk, engages the ring gear so that as the drive disk rotates in the first direction, the spur gear is displaced along the ring gear thus causing the scan disk to rotate in a second direction opposite the first direction causing the second distal end to reciprocate. The beam is coupled through the first channel and the second channel and out of the second distal opening toward the path, thereby causing the beam to scan along the path as the second distal end reciprocates.
Patent DE-69734210-T2 (DE)
Inventor: BERTHON-JONES MICHAEL
IPC: A61F5/56
Filed: 1997-12-18
Granted: 2006-06-22
Abstract: A device (20) for preventing or reducing the passage of air through the mouth (22). The device (20) comprises a top lip member (26) and a bottom lip member (28) having a space (34) therebetween. The space (34) is configured such that, in use, when the top and bottom lips (22T & 22B) of a patient are forced through the space (34), the top and bottom lip members (26 & 28) squeeze the top and bottom lips (22T & 22B) together thereby substantially sealing the mouth (22).
Patent DE-69737814-T2 (DE)
Inventor: FISHER ERIC F
IPC: A01K67/027
Filed: 1997-07-09
Granted: 2008-03-06
Abstract: Disclosed are novel proteins, referred to as tumor necrosis factor binding proteins, that modulate the activity of tumor necrosis factor. Also disclosed are processes for obtaining the tumor necrosis binding proteins by recombinant genetic engineering techniques.
Patent DE-69801210-T2 (DE)
Inventor: ROSEN BERT STEFFEN
IPC: G01N33/86
Filed: 1998-03-19
Granted: 2002-05-02
Abstract: In vitro photometric method for qualitative screening and quantitative determination of the functional activity of components of the Protein C anti-coagulant pathway of blood coagulation, comprising measuring the conversion rate of an exogenous substrate by an enzyme, the activity of which is related to the Protein C anticoagulant activity, in a blood sample of a human comprising coagulation factors and said exogenous substrate after at least partial activation of coagulation through the intrinsic, extrinsic or common pathway and triggering coagulation by adding calcium ions; and comparing said conversion rate with the conversion rate of a normal human blood sample determined in the same way, comprising adding further metal(s) ions to said sample; kits and reagents for use in said method. <IMAGE>
Patent DE-69802935-T2 (DE)
Inventor: BAG IN A BOX LIMITED MANCHESTE
IPC: B65D77/06
Filed: 1998-07-17
Granted: 2002-08-22
Abstract: A container for transporting material, comprises an outer container having first and second container openings therein, and a container liner having first and second liner openings therein. The first liner opening is sufficiently small to be passed through the second container opening and is adapted for connection to the first container opening. The second liner opening is adapted for attachment to the second container opening.
Patent DE-69804855-T2 (DE)
Inventor: MEIJER ALBERTUS
IPC: C01D7/24
Filed: 1998-12-22
Granted: 2002-12-19
Abstract: A process is presented in which anhydrous soda is crystallized and worked up to produce anhydrous soda crystals with a bulk density from 1300 to 1600 kg/m3. The process is characterized in that a solvent is used that allows the crystals to be formed and handled at atmospheric pressure in the presence of water without the monohydrate of soda being formed.
Patent DE-69811392-T2 (DE)
Inventor: FAHNLE WOLFGANG
IPC: B24C5/04
Filed: 1998-11-19
Granted: 2003-12-11
Abstract: The application relates to a process for working a workpiece, in which process an abrasive liquid is sprayed onto the workpiece, via a nozzle, at relatively low pressures which are sufficient to shape and/or polish the surface of the workpiece. The workpiece can be both shaped and polished in a single working step. Abrasive particles or polishing particles may be contained in the abrasive liquid. The pressure of the abrasive liquid lies below 50 bar, preferably below 20 bar. By arranging two nozzles in such a manner that the liquid jets intersect one another at a point, it is possible to set an accurate working depth.
Patent DE-69812356-T2 (DE)
Inventor: BOAZ W
IPC: C07C205/06
Filed: 1998-06-02
Granted: 2003-08-28
Abstract: The preparation of aromatic ketones substituted with a thioether group at the ortho position is accomplished by the initial reaction of an aromatic nucleus substituted with a halide and an ortho nitro group with a nitroalkane in the presence of a hydroxide base. The resulting ortho-nitroalkyl nitroarene compound is converted to the corresponding ortho-nitroaryl ketone by an oxidative Nef reaction. The aromatic nitro group of the ortho-nitroaryl ketone is replaced with a thioether group by reaction with a thiolate anion, most preferably under phase-transfer conditions. Aromatic ketones may be used to prepare various pharmaceutical and herbicidal compounds.